Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr 10:10:20.
doi: 10.21037/tgh-24-121. eCollection 2025.

A new dawn in cancer immunotherapy: the promise of mutant KRAS-specific vaccines

Sheela Ruby Damle  1 , Venu Gopal Pillarisetty  2 , Rachael Ann Safyan  1   3 , Elena Gabriela Chiorean  1   3
Affiliations
Editorial

A new dawn in cancer immunotherapy: the promise of mutant KRAS-specific vaccines

Sheela Ruby Damle et al. Transl Gastroenterol Hepatol. .
No abstract available

Keywords: Cancer vaccine; KRAS; colorectal cancer (CRC); pancreatic ductal adenocarcinoma (PDA).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh-24-121/coif). V.G.P. reports lab research funding from NGM, OncoResponse and Merck and payment from Sensei, Umoja and TriSalus. R.A.S. reports research funding (paid to the institution) by Verastem, Exelixis, Replimune as well as the V Foundation, and advisory board member for Ipsen, Guardant Health, and Agenus. E.G.C. reports advisory board role for Ipsen, Merus, Pfizer, BMS, Takeda, Regeneron, BPGBio, IGM Biosciences, G1 Therapeutics, Merck, Novartis, Astellas, and Foundation Medicine; and research funding, paid to the institution, by Lonza, AffiniT, Erasca, BMS, Novartis, Gilead, Merck, Roche, AADi, Boehringer-Ingelheim, Fibrogen, Cornerstone, Biosplice. The other author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Study design and treatment overview. Created with Biorender software. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; ctDNA, circulating tumor DNA; MRD, minimal residual disease; PBMC, peripheral blood mononuclear cells.
See this image and copyright information in PMC

Comment on

References

    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12-49. 10.3322/caac.21820 - DOI - PubMed
    1. Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol 2021;7:421-7. 10.1001/jamaoncol.2020.7328 - DOI - PMC - PubMed
    1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63. 10.3322/caac.21834 - DOI - PubMed
    1. Tie J, Cohen JD, Wang Y, et al. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncol 2019;5:1710-7. 10.1001/jamaoncol.2019.3616 - DOI - PMC - PubMed
    1. Gong Z, Esmail A, Abdelrahim M. Circulating tumor DNA (ctDNA) and disease recurrence in early stage pancreatic cancer. J Clin Oncol 2023;41:e16313. 10.1200/JCO.2023.41.16_suppl.e16313 - DOI